Palo Alto, CA
Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines for inflammatory diseases.
evommune.comThese are collections Evommune is a part of. Click on the collection name to view similar companies.
Series Unknown
$81,799,952
Series C
$115,000,000
Series B
$7,500,000
Series B
$50,000,000
Series A
$83,000,000
Seed
$12,500,000
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Evommune.